SEC Form 4 · accession 0001140361-17-036059
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 18, 2017 | M | 1,541 | $3.648 | A | 1,541 | D | |
| Common StockF2,F3 | Sep 18, 2017 | S | 356 | $88.1396 | D | 1,185 | D | |
| Common StockF2,F4 | Sep 18, 2017 | S | 700 | $89.1971 | D | 485 | D | |
| Common StockF2,F5 | Sep 18, 2017 | S | 485 | $89.9919 | D | 0 | D | |
| Common Stock | Sep 19, 2017 | M | 1,541 | $3.648 | A | 1,541 | D | |
| Common StockF2,F6 | Sep 19, 2017 | S | 497 | $87.8609 | D | 1,044 | D | |
| Common StockF2,F7 | Sep 19, 2017 | S | 944 | $89.1785 | D | 100 | D | |
| Common Stock | Sep 19, 2017 | S | 100 | $89.76 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F8 | $3.648 | Sep 18, 2017 | M | 1,541 | D | — | Jun 18, 2024 | Common Stock | 1,541 | 124,330 | D |
| Employee Stock Option (right to buy)F8 | $3.648 | Sep 19, 2017 | M | 1,541 | D | — | Jun 18, 2024 | Common Stock | 1,541 | 122,789 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2Represents the aggregate of sales effected on the same day at different prices.
- F3Represents the weighted average sales price per share. The shares sold at prices ranging from $87.68 to $88.53 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $88.75 to $89.43 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5Represents the weighted average sales price per share. The shares sold at prices ranging from $89.81 to $90.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F6Represents the weighted average sales price per share. The shares sold at prices ranging from $87.42 to $88.11 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F7Represents the weighted average sales price per share. The shares sold at prices ranging from $88.65 to $89.55 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F8The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.